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Potent human immunodeficiency virus-neutralizing and
complement lysis activities of antibodies are not obligatorily
linked
Abstract
To evaluate the contribution of complement-mediated lysis to the in vivo activities of neutralizing
antibodies, we analyzed the influence of complement activation on treatment success in a recent passive
immunization trial with the neutralizing monoclonal antibodies 2G12, 2F5, and 4E10. Administration of
monoclonal antibodies led to an immediate, high activation of the complement system even in the
absence of viremia in the 14 participating human immunodeficiency virus-infected individuals. Lysis
activity measured in patient plasma increased during passive immunization; however, the increases were
modest and only partially attributable to the administration of antibodies. We found that unlike
neutralization activity, lysis activity was not associated with treatment success in this trial. Compared to
complement lysis mounted by the polyclonal antibody response in vivo, monoclonal antibodies were
weak inducers of this activity, suggesting that polyclonal responses are more effective in reaching the
required threshold of complement activation. Importantly, strong neutralization activity of the
monoclonal antibodies did not predict complement lysis activity against patient and reference viruses,
suggesting that these activities are not linked. In summary, our data support the notion that the in vivo
activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated
mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity.
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To evaluate the contribution of complement-mediated lysis to the in vivo activities of neutralizing antibodies,
we analyzed the influence of complement activation on treatment success in a recent passive immunization trial
with the neutralizing monoclonal antibodies 2G12, 2F5, and 4E10. Administration of monoclonal antibodies
led to an immediate, high activation of the complement system even in the absence of viremia in the 14
participating human immunodeficiency virus-infected individuals. Lysis activity measured in patient plasma
increased during passive immunization; however, the increases were modest and only partially attributable to
the administration of antibodies. We found that unlike neutralization activity, lysis activity was not associated
with treatment success in this trial. Compared to complement lysis mounted by the polyclonal antibody
response in vivo, monoclonal antibodies were weak inducers of this activity, suggesting that polyclonal
responses are more effective in reaching the required threshold of complement activation. Importantly, strong
neutralization activity of the monoclonal antibodies did not predict complement lysis activity against patient
and reference viruses, suggesting that these activities are not linked. In summary, our data support the notion
that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated
mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity.
The past decades have shaped our understanding of the role
of neutralizing antibodies in inhibiting human immunodefi-
ciency virus type 1 (HIV-1) transmission and replication in the
infected host. Evidence of their impact in the course of natural
infection is based on observations that antibody responses are
subject to rapid viral escape (2, 3, 29, 32, 37, 42, 64, 65) and
passive immunization studies with animals (19, 21, 28, 36, 38)
and humans (61). Despite the knowledge gained regarding
their activities, the exact modes of antibody action in vivo
remain unclear. While neutralization, defined as the direct
interaction of the antibody with the virion that obstructs infec-
tion of the target cells, is considered a principal mechanism in
viral defense, antibodies also contribute to protection against
viral pathogens by inducing phagocytosis, antibody-dependent
cellular cytotoxicity, and activation of the complement system,
leading to the destruction of the virus and infected cells (8, 20,
21, 26). Which of these antibody-mediated mechanisms, neu-
tralization or effector functions, contribute most to viral con-
tainment in HIV infection and thus should be elicited by pro-
tective vaccines remains to be defined (25).
Lysis of HIV-1 upon antibody-mediated activation of the
complement system has been demonstrated in vitro (51–53)
and ex vivo (1, 24, 59). In vivo, antibodies inducing comple-
ment lysis were found to have an impact on viremia control
during the acute phase of infection (24). These responses in-
crease during the chronic infection phase and appear to be
maintained throughout the course of the disease (1, 24, 51, 52,
59). Previous studies suggested that nonneutralizing antibodies
dominate in this mechanism (1, 24). Nevertheless, complement
has also been found to boost the activities of neutralizing
antibodies in vitro and in vivo (17, 24, 39).
Although antibodies eliciting complement lysis can be de-
tected at all disease stages, their activities are not high titered
(24, 59), which is attributed to the ability of the virus to coun-
termeasure complement attack by incorporating several host
cell-derived complement control proteins (47, 48, 56). The
latter raised concerns that substantial proportions of comple-
ment-opsonized virions not only remain intact but also may
gain an increased capacity to infect complement receptor-ex-
pressing cells, as suggested by several in vitro studies (5, 6, 23,
30, 55, 58). Whether lysis or enhancement dominates the ac-
tivity of antibody and complement on HIV infection in vivo
and if and how the balance between beneficial and detrimental
antibody function is maintained during disease progression
thus remain central questions.
In the present study, we sought to define whether antibody-
mediated complement lysis of HIV-1 virions contributes to the
in vivo activities of neutralizing antibodies and, if so, what the
relative contribution of this defense mechanism is. We ad-
dressed this question in a retrospective analysis of a passive
immunization study with neutralizing antibodies 2G12, 2F5,
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and 4E10 in 14 HIV-infected individuals where a mix of these
three monoclonal antibodies (MAbs) delayed viral rebound
after cessation of therapy (61). Here, we analyzed patient
plasma collected throughout the trial for complement activa-
tion, lysis activity, and neutralization capacity against the au-
tologous isolate and the heterologous virus strain JR-FL. In
addition, to verify our ex vivo findings, we investigated the
complement lysis activities of MAbs 2G12, 2F5, and 4E10
individually in vitro.
MATERIALS AND METHODS
Patients, virus isolates, and plasma. Plasma samples from six acutely and eight
chronically HIV-1-infected patients derived during a passive immunization trial
with neutralizing antibodies 2G12, 2F5, and 4E10 (61) were studied. Patient
demographics and isolation of autologous virus were described previously (46,
61). Patient isolates used in this study were derived before the passive immuni-
zation study (pretreatment time point) (61). Virus stocks of patient isolates used
in lysis assays were produced on CD8-depleted peripheral blood mononuclear
cells (PBMCs) as described previously (61).
Patient blood was sampled in EDTA Vacutainers (Becton Dickinson), and
plasma was collected within 6 h after the blood draw and frozen in 1-ml aliquots
at 75°C. Plasma was heat inactivated (1 h at 56°C to inactivate autologous
complement activity) and centrifuged at 500  g for 10 min before use to remove
cell debris and lipids. Normal human plasma used as a control was treated
identically as patient plasma.
Written informed consent was obtained from all patients and HIV-1-negative
blood donors according to guidelines of the local ethics committee.
Measurement of complement activation. Plasma levels of complement com-
ponents C3 (54) and terminal complement complex (TCC) (40, 66) were mea-
sured by enzyme-linked immunosorbent assay. Levels of C3a were measured by
a commercial enzyme-linked immunosorbent assay kit (Quidel) as recommended
by the manufacturer.
Neutralization assays. Neutralization activity reported in this study was mon-
itored in the frame of previous studies (61, 62). Neutralization activity mediated
by the passively immunized antibodies in patient plasma has been assessed using
a TZM-bl cell-based neutralization assay and 293T cell-produced reporter gene
virus together with an arithmetic approach that allows the dissection of MAb
mediated from autologous antibody activity as described previously by Trkola et
al. (62). The MAb activity in plasma is therefore reported as the reciprocal
plasma dilution causing a 70% reduction in luciferase reporter gene expression.
Activities against both the autologous isolate and the heterologous virus JR-FL
were measured and used for analyses in the current study.
Since lysis activity was measured against PBMC-derived virus, for direct com-
parison with in vitro MAb-mediated lysis activity, we utilized neutralization
activities determined in a PBMC-based assay system (61). Here, the MAb con-
centration causing 90% inhibition (IC90) of viral replication as determined by
p24 antigen production is reported. For the mix of the three MAbs, the total IC90
of an equimolar mix is reported.
HIV-1 virion complement lysis assay. Complement-mediated lysis activity was
measured by a real-time PCR-based assay as described previously (24). A mix of
four to five human healthy donor sera stored at 75°C was used as the source of
complement. Briefly, virus was incubated with patient plasma (final dilution, 1:5),
complement (final dilution, 1:2), RNase A (Qiagen), and RPMI 1640 medium
(BioWhitaker) in a total volume of 100 l for 3 h at 37°C. The reaction mixture
was then subjected to a freeze-thaw cycle and treated with RNase A (Qiagen)
and DNase I (Roche) for 1 h at 37°C (14). Digestion was stopped by adding
protease (Qiagen). Residual viral RNA was extracted from intact virions
(MagNa Pure LC; Roche) and quantified by real-time PCR.
For each individual assay, samples were tested in triplicates. Complement-
mediated lysis activity was expressed as the percentage of lysed HIV-1 RNA
copies compared to control plasma treatment. A mix of five HIV-1-negative
healthy donor plasmas was used as the negative control (no lysis activity, 0%
value).
In vitro lysis activities of MAbs were measured analogously using 25 g/ml of
each antibody in RPMI medium instead of patient plasma, and medium alone
was used as the negative control.
Real-time PCR. HIV-1 virions were quantified using primers to the 5 end of
HIV RNA as described previously (mf86, cr1, and cr2) (24). For detection, a
dual-labeled fluorescent probe with a 6-carboxyfluorescein moiety at its 5 end
and a 6-carboxytetramethylrhodamine moiety at its 3 end was used (mf74tq)
(24). PCR was performed as described previously (13, 43) using a single-tube
system (Qiagen one-step reverse transcription-PCR) and an additional “hot
start” using Paraplast (Fluka) to separate cDNA synthesis and PCR amplifica-
tion. cDNA synthesis and subsequent amplification were performed in duplicates
in a real-time thermocycler (i-Cycler; Bio-Rad) as described previously (13, 43).
Statistical analysis. Data analyses were performed using Prism, version 4.03,
for Windows (GraphPad Software) and Stata SE/10 for Windows (Stata Corp.).
Because of the longitudinal nature of our study, repeated measurements with
more than two data points per patient were performed. Therefore, we could not
use standard statistical techniques such as t tests. Instead, we used linear regres-
sion models with robust standard errors, which allow the modeling of longitudi-
nal data with more than two measurements per patient. Analogous to t tests,
specific subgroup comparisons were then performed based on the coefficients
and standard errors from the regression models with the Wald test (41).
Correlation analysis was performed using Spearman’s rank correlation. Tests
of significance were two tailed unless indicated otherwise.
RESULTS
Passively administered MAbs activate the complement sys-
tem. To obtain insights into whether neutralizing antibody
function in vivo includes the activation of defense mechanisms
mediated by the complement system, we quantified plasma
levels of the complement components C3, C3a, and TCC dur-
ing 12 weeks of passive immunization with neutralizing MAbs
2G12, 2F5, and 4E10. Blood for these analyses was collected
immediately before and after infusion of the three MAbs. Each
infusion cycle consisted of a consecutive infusion of the three
individual MAbs. The time window between initiation of the
first infusion and completion of the last was usually 90 min (30
min per antibody), with the exception of the first infusion,
where each antibody was infused over a 60-min period. As
activation of the complement system is known to occur within
minutes (35, 68), this allowed us to monitor complement acti-
vation in the investigated time frame. We found that the ad-
ministration of the antibodies induced a decrease in plasma
levels of complement component C3 (mean change, 293
g/ml [95% confidence interval, 471 to 115 g/ml] [P 
0.003]), while those of the cleavage product C3a (mean change,
57 ng/ml [95% confidence interval, 51 to 88 ng/ml] [P 
0.57]) and the TCC (mean change, 865 ng/ml [95% confidence
interval, 660 to 1,069 ng/ml] [P  0.001]) increased, indicating
that the three MAbs induced strong complement activation
(Fig. 1). Notably, however, activation had already occurred at
the first time point (week 0) in the absence of any viremia when
patients were still on antiretroviral therapy (ART) as exempli-
fied for the changes in C3 levels during the course of treatment
in patient NAB11 (Fig. 1A). This was substantiated when we
analyzed all three parameters across all patients (Fig. 1B to D).
Activation of complement, indicated by the magnitude of
change between pre- and postinfusion measurements, did not
appear to increase over time (C3 change per week of 7.0
g/ml [95% confidence interval, 35.2 to 21.2 g/ml] [P 
0.60]; C3a change per week, 23.6 ng/ml [95% confidence in-
terval, 1.1 to 46.1 ng/ml] [P  0.04]; TCC change per week, 3.1
ng/ml [95% confidence interval, 14.44 to 20.65 ng/ml] [P 
0.71]), nor was complement activation associated with the in
vivo plasma levels of the MAbs with the exception of 2G12 and
the increase of C3a (r  0.32; P  0.0001). In summary, the
quantification of complement components indicated that the
complement system was strongly activated in vivo by MAbs
2G12, 2F5, and 4E10 independently of viral replication but did
not provide insight into a potential contribution to virus lysis.
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Whether lysis did not occur or whether the relative contribu-
tion of lysis-associated complement activation (TCC) was too
low to be detected could not be verified in this analysis.
High level of complement activation by the MAbs did not
trigger infection enhancement in vivo. A major concern with
respect to antibody-mediated effector mechanisms in vivo re-
mains the possibility that Fc receptor (FcR) and complement
receptor interactions may lead to the enhancement of infec-
tion, as demonstrated under certain in vitro conditions (5, 6,
31, 33, 57). During the investigated passive immunization trial,
patient virus rebounded upon escape to antibody 2G12 (27,
61). Antibody treatment was continued for the entire 12-week
study period, irrespective of when the antibodies had lost the
capacity to control viremia and rebound had occurred. Nota-
bly, while rebounding virus had lost sensitivity to 2G12, virus
isolates from all patients retained their sensitivities to 2F5 and
4E10. Theoretically, in a setting where antibodies are present
in abundance but neutralization activity is too low to show
effect, enhancing mechanisms may be particularly prone to
occur. To assess whether antibodies prompted infection en-
hancement in vivo, we compared viral set points reached in
each individual in presence of MAbs to those in the absence of
MAbs. Viral load before the last instance of ART was compa-
rable with the viral set point during passive immunization
among patients who lost control of viremia while still receiving
MAb treatment, indicating that MAbs did not enhance infec-
tivity in the absence of inhibitory activity (mean change for
noncontrollers, 0.01 log viral load [95% confidence interval,
0.61 to 0.59] [P  0.98]) (Fig. 2) (see Table S1 in the sup-
plemental material). When we analyzed the effects on viral
load upon washout of the MAbs in noncontrollers, no differ-
ences in virus load in the presence (week 12) or absence (week
24) of antibodies were observed (mean change, 0.12 log viral
load [95% confidence interval, 0.42 to 0.18] [P  0.40]),
indicating that despite the high level of complement activation,
the MAbs had no enhancing effect on viral replication. Al-
though it cannot be ruled out that in other settings during
natural HIV infection, antibody-mediated enhancement
through complement or FcR-dependent mechanisms may oc-
cur, our analysis failed to substantiate a prominent role of this
mechanism in vivo.
Longitudinal analysis of autologous complement-mediated
lysis activity. To assess if the passively administered antibodies
elicited complement-mediated lysis of the virions, lysis activity
against the autologous virus isolate derived before the passive
immunization was measured in patient plasma before antibody
infusion (week 0), before the last infusion (week 12), when
most patients had the highest antibody trough levels, and after
washout of the antibodies (week 24). We observed virolysis
activity in 12 out of 14 individuals before passive immunization
and antibody infusion led to a notable increase in this activity
FIG. 1. Complement is activated during passive immunization in-
dependent of viremia. Plasma levels of complement components were
measured before and after the infusion of a mix of MAbs 2G12, 2F5,
and 4E10. Levels of C3 before infusion (open circles) and after infu-
sion (closed circles) are shown for patient NAB11 (A) together with
the viral load (solid line) for weeks 1 to 11. Shaded areas indicate
complement activation. Median levels of C3 (B), C3a (C), and TCC
(D) before (open symbols) and after (closed symbols) infusion are
shown for all 14 patients. Error bars show 95% confidence intervals.
FIG. 2. Complement activation by 2G12, 2F5, and 4E10 did not
trigger infection enhancement. Activation of complement by MAbs
has neither a decreasing nor an enhancing effect on viral set point in
noncontrolling patients. Dashed lines represent noncontrollers, and
solid lines represent controllers. Means for controllers (closed squares)
and noncontrollers (open squares) and 95% confidence intervals (er-
ror bars) from a multivariable linear regression model with a robust
variance estimator are shown.
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(Table 1 and Fig. 3A and B). Virus lysis activity increased in
both chronic patients (mean change in lysis activity, 18.8%
[95% confidence interval, 3.0% to 34.5%] [P  0.02]) and
acute patients (32.9% [95% confidence interval, 14.9% to
50.9%] [P  0.002]) (see Table S3 in the supplemental mate-
rial) between week 0 and week 12. This elevation could be due
to both the administered MAbs present at week 12 and a
boosted autologous antibody response. The latter is known to
occur upon resuming viral replication following treatment in-
terruption (60).
Notably, however, among most chronically HIV-infected in-
dividuals, lysis activity dropped to the preimmunization level
after washout of the antibodies by week 24, indicating that the
passively administered MAbs contributed to the elevated lysis
activity observed at week 12 (Fig. 3A) (see Table S3 in the
supplemental material). Interestingly, patients with acute HIV
infection preserved heightened lysis activity even after washout
of the MAbs (Fig. 3A). In this group of individuals, viral
rebound occurred later than in chronically infected patients
(weeks 5 to 24 for patients with acute infection and weeks 2
to 18 for patients with chronic infection) (61), and conse-
quently, the induction of autologous antibody responses fol-
lowing viral rebound will have peaked in most patients with
acute infection after week 12. To what extent the increases in
lysis activity at week 12 were mediated by autologous antibody
or MAb is thus difficult to assess in the setting of acute infec-
tion but likely is associated to some extent with MAb activity as
observed in chronic infection (Table 1 and Fig. 3A). When we
stratified patients into responders and nonresponders based on
whether or not MAb treatment led to a delay in viral rebound,
we observed a similar pattern of reactivities for responders and
patients with acute infection and nonresponders and chroni-
cally infected individuals (Fig. 3B). The latter is not unex-
pected, as the majority of nonresponders were individuals with
chronic infection (six out of eight patients), and responders
were found mostly among patients with acute infection (four
out of six patients) (Table 1). Since MAb levels and lysis
activities varied substantially among individuals, we investi-
gated to what extent the plasma antibody levels reached among
chronically infected individuals reflected the increases in vi-
rolysis activity measured ex vivo. A correlation analysis re-
vealed no association (r value of 0.42 and P value of 0.16 for
2G12, r value of 0.33 and P value of 0.27 for 2F5, and r value
of 0.04 and P value of 0.91 for 4E10) (Fig. 3C), suggesting
that the concentration of the MAbs was not a limiting factor
and/or that the overall contribution of the MAbs to lysis activ-
ity must be low.
The mean increase in lysis activity attributable to the MAbs
in chronic infection was 23.5%. However, neither total lysis
activity measured at week 12 nor the increase over baseline
levels at this time point was associated with response to the
passive immunization treatment (Fig. 3D).
Neutralization and lysis activities of passively administered
antibodies 2G12, 2F5, and 4E10 are not linked. In order to
investigate if the requirements for high efficiency in neutral-
ization and complement lysis activity are related, we analyzed
the effects of the three neutralizing MAbs in both activities. In
a longitudinal assessment of the neutralization activities
against the heterologous reference strain JR-FL throughout
the passive immunization trial, we previously established that
all three MAbs were active in vivo and that neutralization
activity against JR-FL was mediated predominantly by the
administered MAbs (61, 62). However, here, we found no
correlation between lysis activity against JR-FL and patient
virus isolates measured in plasma during the trial (week 12)
(Table 1) and the MAb-mediated neutralization activity
against these viruses at the same time point (62), indicating
that there is no direct relationship between the two antibody
functions (r value of 0.11 and P value of 0.72 for autologous
TABLE 1. Autologous and heterologous complement-mediated lysis activities during passive immunization against autologous pretreatment
virus isolatesa
Patient Infection phase Viremia control
% Autologous virolysis 	%
 % Heterologous JR-FL virolysis
Preb Wk 0c Wk 12d Wk 24e Preb Wk 0c Wk 12d Wk 24e
NAB 01 Chronic No 71.2 83.8 89.6 87.6 6.5 9.8 43.3 35.2
NAB 02 Chronic No 54.3 40.3 52.9 24.9 18.2 7.9 49.7 36.3
NAB 03 Chronic Yes 36.5 31.8 77.3 56.8 40.7 40.7 48.1 65.0
NAB 04 Chronic Yes 16.1 18.3 44.7 27.6 68.6 63.7 73.3 72.4
NAB 05 Chronic No 65.6 59.8 71.7 67.0 61.9 42.3 56.4 50.5
NAB 06f Chronic No 87.4 83.6 ND NA ND ND ND NA
NAB 07 Chronic No 34.9 35.8 78.9 45.4 10.2 0.3 47.3 25.4
NAB 08 Acute Yes 29.3 18.1 75.7 52.7 38.2 17.2 44.3 54.8
NAB 09 Chronic No 49.7 52.6 71.6 40.6 41.8 38.9 68.4 48.8
NAB 10 Acute No 5.8 5.3 45.1 46.2 0.6 27.4 56.6 36.6
NAB 11 Acute No 9.9 18.7 59.5 58.6 51.7 49.3 50.7 68.9
NAB 12 Acute Yes 3.1 19.6 60.9 56.8 4.3 25.0 39.9 47.2
NAB 13 Acute Yes 10.1 30.1 46.1 50.7 0.0 4.9 13.7 21.6
NAB 14 Acute Yes 48.1 53.4 55.3 37.1 56.4 38.2 18.7 26.4
a Means (95% confidence intervals) from the multivariable linear regression model were 39.4% (24.9% to 53.8%) at week 0, 63.8% (54.8% to 72.8%) at week 12,
and 50.2% (40.0% to 60.3%) for autologous virolysis and 21.9% (5.3% to 38.4%) at week 0, 47.0% (36.6% to 57.3%) at week 12, and 45.3% (34.9% to 55.7%) at week
24 for heterologous virolysis (see Table S2 in the supplemental material). NA, not applicable; ND, not done.
b Before last ART.
c Before antibody infusion.
d At highest antibody trough level.
e After wash-out of the antibodies.
f Patient NAB 06 stopped the passive immunization study after week 12 and went back on ART.
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activity and r value of 0.20 and P value of 0.50 for heterologous
lysis activity) (Fig. 3E and F).
To verify our ex vivo analysis, we performed in vitro lysis
assays with antibodies 2G12, 2F5, and 4E10 and with a mix of
these three MAbs. Lysis activity against the virus isolates from
the 14 patients that participated in the passive immunization
trial and four reference strains varied broadly (Fig. 4A and B).
Despite the relatively high concentrations probed, none of the
MAbs by themselves reached lysis activity above 50% against
any of the 18 virus strains tested. Antibodies 2G12 and 2F5
elicited lysis activity that was above 30% against only a single
isolate (NAB03). In contrast, 4E10 by itself as well as the mix
of the three antibodies showed evidence for lysis activity that,
although still low, was significantly above background (0.2%
[95% confidence interval, 9.0 to 9.3] [P  0.97] for 2G12,
7.6% [95% confidence interval, 17.4% to 2.2%] [P  0.12]
for 2F5, 16.8% [95% confidence interval, 8.2% to 25.4%] [P 
0.001] for 4E10, and 21.6% [95% confidence interval, 10.1% to
33.1%] [P  0.001] for the mix by one-sample t test) (Fig. 4).
This relatively weak capacity of monoclonal neutralizing anti-
bodies to elicit virus lysis appears to be common, as MAb b12
also has only low lysis activity (11.8% [95% confidence interval,
3.4% to 20.3%] [P  0.01]). Interestingly, in passive immuni-
zation experiments in the macaque model, it was recently
shown that complement activity does not contribute to b12
protection against strain SHIVSF162P3 in vivo (21). In agree-
ment with this, we found that b12 by itself harbors no/low
activity against the parental HIV strain SF162 (Fig. 4).
Overall, while the three MAbs potently neutralized most of
the patient viruses, they failed to effectively lyse these isolates
(Fig. 5). When the MAbs were probed in vitro in the absence
of patient antibodies, no or only marginal lysis activity was
FIG. 3. Passively administered antibodies 2G12, 2F5, and 4E10 can contribute to in vivo complement lysis, but activity is low. Autologous lysis
activities in patients with acute (triangles) and chronic (circles) infection (A) as well as in controller (closed squares) and noncontroller patients
(open squares) (B). Means and 95% confidence intervals (error bars) from a multivariable linear regression model with robust variance estimator
are shown (see Table S3 in the supplemental material). (C) Correlation analysis of MAb concentration in vivo and complement lysis activity. Week
12 plasma levels of MAb 2G12 (dots), 2F5 (triangles), and 4E10 (diamonds) do not correlate with matched plasma complement lysis activity against
autologous virus. (D) Neither total lysis activity at week 12 nor the absolute increase in lysis activity from weeks 0 to 12 differs between controller
and noncontroller patients. Means and 95% confidence intervals (error bars) are shown. (E and F) MAb-mediated neutralization in patient plasma
at week 12 and complement lysis activity from the same time point against autologous (E) and heterologous (F) virus is not correlated.
MAb-mediated 70% neutralization (NT70) was determined previously using a TZM-bl cell-based neutralization assay (62).
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detectable in most cases. Notably, however, the mean lysis
activities of 4E10 and the triple combination reached in vitro
against the viruses derived from trial participants were in the
ranges of increases measured in patient plasma ex vivo (16.8%
for 4E10 and 21.6% for the triple mix) (Fig. 4).
In sum, these analyses revealed that compared to the lysis
activities mounted by the polyclonal antibody response in vivo,
MAbs by themselves are weak inducers of this activity. Al-
though the MAbs tested clearly had the capacity to bind to
virions, as they were able to neutralize, we found that the
ability to bind and neutralize provided no indication of the
efficiency of a given antibody to induce complement lysis. We
found neither a common pattern of antibody lysis and neutral-
ization activity against the tested virus isolates nor interdepen-
dencies between these activities (r value of 0.08 and P value of
0.78 for 2G12, r value of 0.14 and P value of 0.64 for 2F5, r
value of 0.33 and P value of 0.25 for 4E10, and r value of
0.48 and P value of 0.08 for the equimolar mix of the three
MAbs). Our analysis thus strongly suggests that complement
lysis activity cannot be predicted by neutralization activity.
DISCUSSION
To our current understanding, neutralizing antibodies are a
key immune defense mechanism against HIV (10, 11). Al-
though their activities have been ascertained in a compelling
number of in vitro and in vivo studies (4, 17, 19, 22, 28, 32, 36,
38, 42, 45, 50, 61, 65), we still lack information on whether
antibodies act solely by directly binding and neutralizing the
virus particle or by eliciting effector functions of the immune
system (20, 21, 24, 25). In the present study, we addressed this
question by assessing if complement-mediated lysis contributes
to the in vivo effect of neutralizing antibodies. The comple-
ment system can be activated by direct binding of complement
components to HIV or more potently via antibodies bound to
the particle (49, 53, 55), which can result in complement attack
and lysis of the particle (1, 24, 59). In the current study, our
primary interest was to define whether neutralizing antibodies,
upon binding to viral particles, induce the activation of the
complement cascade in vivo and trigger lysis of the virus. Uti-
lizing specimens collected during a passive immunization trial
with the three neutralizing MAbs 2G12, 2F5, and 4E10, we
were able to assess the influence of MAb administration on
neutralization, complement activation, and lysis activities in
patients who responded and in those that did not respond to
FIG. 4. MAbs have weak lysis activity in vitro. (A) Lysis activities of
neutralizing MAbs 2G12, 2F5, 4E10, and b12 were tested against the
14 patient virus isolates. Only 4E10, the mix of 2G12/2F5/4E10, and
b12 show moderate lysis activity. Error bars show 95% confidence
intervals (one-sample t test). (B) Lysis activities of 2G12 (circles), 2F5
(triangles), 4E10 (diamonds), and b12 (squares) against reference vi-
ruses. Error bars show standard deviations of triplicate measurements.
FIG. 5. In vitro neutralization activity does not predict complement
lysis activity. Lysis activities (shown as bars) of MAbs 2G12, 2F5, and
4E10 and the mix of these three antibodies against the 14 patient virus
isolates do not show a common pattern. Neutralization activities (IC90
values, inverse logarithmic scale) of MAbs 2G12 (circles), 2F5 (trian-
gle), and 4E10 (diamonds) and the mix of the three MAbs (open
squares) in a PBMC-based neutralization assay against each virus is
depicted above the corresponding bars. The IC90s of the individual
MAbs and the equimolar mix of the MAbs were determined using a
PBMC-based neutralization assay (61). Error bars show standard de-
viations of triplicate measurements.
VOL. 82, 2008 COMPLEMENT LYSIS BY NEUTRALIZING ANTIBODIES 3839
 at UNIVERSITATSSPITAL on M
arch 25, 2008 
jvi.asm.org
D
ow
nloaded from
 
passive immunization treatment by controlling viremia re-
bound (61).
The complement cascade was highly activated in all study
participants upon passive immunization. However, this was not
a direct indication of ongoing virus lysis, as activation also
occurred in the absence of detectable viremia as an immediate
consequence of immunoglobulin administration. Antibody
preparations used for passive immunization were controlled to
ensure that no or only low amounts of aggregates were con-
tained to limit immune activation (data not shown). Neverthe-
less, as evident from our study and from previous reports in the
literature, the high concentration of antibodies administered
remains by itself conceivably sufficient to induce complement
activation in vivo (12, 63). Activation of the complement sys-
tem due to the binding of MAbs to virions (which consequently
leads to their destruction) appears to be minute compared to
this high “background” activation upon the administration of
the MAbs, as we did not observe an increase in complement
activation when virus became detectable in patients. Comple-
ment activation levels in our study therefore did not provide
insight into a potential contribution toward virus lysis.
In all patients, complement-mediated lysis activity increased
during the trial, which can be attributed to both the activities of
the MAbs and a boost of the autologous response known to
occur upon viral rebound (60). The latter may explain the
observation that among acutely HIV-infected patients, lysis
activity levels remained elevated compared to pretreatment
levels even after washout of the MAbs (Fig. 3A). Early anti-
retroviral treatment prevents a full maturation of humoral
immune responses, which has been found to fully develop and
profoundly increase only upon resuming viral replication after
cessation of ART (7). This also appears to be the case in our
cohort: while pretreatment lysis activity was somewhat lower
among individuals with acute infection (mean difference in
lysis activity, 26.6% [95% confidence interval, 50.5% to
2.6%] [P  0.03]), no difference between acute and chroni-
cally infected individuals was observed upon completion of the
trial (mean difference in lysis activity, 0.37% [95% confi-
dence interval, 20.4% to 19.7%] [P  0.97]). For chronic
patients, whose antibody responses have already matured and
are expected to reach a steady-state level more rapidly upon
rebound, our data suggest that the MAbs had a modest impact
on the overall lysis activity. Although the induction of autolo-
gous responses overlapped with MAb administration in these
individuals and the effects of passively administered and autol-
ogous antibody responses cannot be dissected apart, it is fea-
sible to assume that the MAbs had a similar impact on lysis
activity, as seen in chronically infected individuals. Overall,
increases in lysis activity were moderate and not paralleled by
an increase in complement activation, which is probably due to
the fact that the complement activation leading to virolysis,
induced by autologous antibodies and MAbs, is low compared
to the strong background activation induced by the passively
transferred MAbs themselves.
The rise and fall in lysis activity that parallel the adminis-
tration and washout of MAbs in chronically infected patients in
our analysis provide the best evidence that the MAbs are
capable of inducing modest complement lysis in vivo either by
themselves or in combination with the autologous response
(Fig. 3A and B). However, in general, the lysis activity of MAbs
was low compared to the activity observed in the autologous,
polyclonal antibody response, suggesting that polyclonal re-
sponses are more effective in inducing the threshold for com-
plement cascade activation. Our study further substantiates the
evidence that antibodies mediating complement lysis of HIV
are common at all stages of HIV infection, that the mediated
activity is comparatively low titered, and that polyclonal re-
sponses appear to be more effective in mediating this activity.
While overall, a modest increase in lysis activity occurred
upon passive immunization, we did not find evidence that this
was linked to the protective effect of the MAbs, as increases in
controlling and noncontrolling patients were comparable (Fig.
3D). We therefore conclude that the in vivo activities of the
administered neutralizing antibodies 2G12, 2F5, and 4E10
likely were dominated by the direct neutralization of free virus
or FcR-mediated mechanisms such as phagocytosis and anti-
body-dependent cellular cytotoxicity. This supports observa-
tions made by Hessell and colleagues using wild-type and ef-
fector function-defective variants of neutralizing antibody b12
(21), where they reported that MAb b12 displays no comple-
ment-mediated antiviral activity in protecting rhesus macaques
against infection with SHIVSF162P3. Based on our data, this is
not unexpected but does not allow us to infer with certainty
that, in general, complement-dependent mechanisms do not
contribute to neutralizing antibody activity in vivo, as b12 by
itself fails to induce complement lysis of SF162 (Fig. 4B).
Notably, all four MAbs tested displayed hardly any lysis
activity. The detected activities were restricted mostly to MAbs
4E10 and b12. However, even there, the activities were very
low and clearly beyond the activity of the polyclonal autolo-
gous antibody response. The finding that antibodies can harbor
in vitro neutralization but no measurable lysis activity against
specific isolates (Fig. 5) is striking and asks for further assess-
ment of the underlying mechanisms. The incapacity to induce
lysis activity could be due to a lack of binding sites on func-
tional envelope spikes for these neutralizing antibodies, as a
certain density of antibody binding sites will be required to
prompt the activation of the classical complement pathway (9,
44). On the other hand, the threshold in antibody binding to
induce neutralization could be relatively low and might require
only a single bound antibody according to a model described
previously by Yang et al. (67). In support of this, we found that
while neutralization activity of the MAbs against the tested
virus strains was generally high, lysis activity was rarely medi-
ated and, if so, at comparatively low levels. This is in contrast
to patient sera, which mediate significant lysis activity (24),
indicating that polyclonal responses may be needed to reach
the threshold of effective complement lysis, as previously sug-
gested (53). We and others observed previously that lysis ac-
tivity against HIV plateaus at about 90% lysis of virus irrespec-
tive of the concentration of MAbs or patient sera used (24, 59).
The remaining 10% of virions remain protected from virolysis,
which could be similarly caused by a lack of binding sites on
these virions or, alternatively, by a higher incorporation of
complement control proteins in these virions.
While neutralizing antibodies need to bind to functional
trimers in order to inhibit virus infectivity (16), lysis-inducing
antibodies could theoretically bind anywhere on the virion, i.e.,
to nonfunctional trimers, monomers, and uncleaved gp160 and
gp41 stumps (34). However, a lack of density of the appropri-
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ate epitopes alone does not explain the differential perfor-
mance of the neutralizing antibodies probed in our study in
eliciting virus lysis. While 2G12 and b12 neutralized the ma-
jority of virus isolates tested (61) (data not shown), and both
are able to bind gp120 in the context of the monomer and
trimer and should consequently have comparable numbers of
binding sites on the virion available, only b12 showed measur-
able lysis activity. The same was true for the membrane-prox-
imal external region-specific MAbs, where 4E10 but not 2F5
induced the lysis of the majority of isolates. This is particularly
surprising, as the MAbs are directed to adjacent domains in
the viral envelope and, like 2G12, are engineered proteins that
share an identical Fc region. The latter suggests that additional
factors such as accessibility, spatial arrangement, and mem-
brane distance of the epitopes shape the lysis activities of
individual antibodies. To what extent neutralizing and/or non-
neutralizing antibodies elicited by the autologous immune re-
sponse in vivo trigger complement defense mechanisms, how
the activities of neutralizing and lysis-inducing antibodies over-
lap, and which epitopes are recognized by these antibodies are
currently unknown and will require further investigations to
define the mechanisms of their action and in vivo relevance.
Notably, the efficacy of complement-mediated lysis of HIV-
infected cells deserves to be explored in this respect, as effector
mechanisms targeting infected cells may be of particular im-
portance in controlling infection. Equally, phagocytosis of an-
tibody-opsonized virus may be a relevant yet not-quantified
factor in eliminating infectious virus. Research efforts in recent
years have highlighted the potency of the humoral immune
response (1, 15, 18, 21, 24) but have also made it evident that
a detailed assessment of the relative contribution of direct and
effector-mediated antibody functions to virus containment in
vivo is a necessity to define relevant immune responses and
direct future vaccine design.
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